JRCT ID: jRCT1021210071
Registered date:02/03/2022
A study aimed at exploring the relationship between brain imaging, cognitive function and EEG in healthy individuals and patients with Alzheimer's disease.
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Alzheimer's disease |
Date of first enrollment | 04/04/2022 |
Target sample size | 95 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | Cognitive function test EEG test Amyloid PET scan |
Outcome(s)
Primary Outcome | Relationship between qualitative assessment of amyloid beta and features obtained from EEG (EEG features) |
---|---|
Secondary Outcome | The relationship between the MMSE and EEG features (EEG features) Relationship between MoCAJ and features obtained from EEG (EEG features) Summary statistics for MMSE and MoCAJ Amyloid beta Quantitative Assessment Relationship between quantitative assessment of amyloid beta and features obtained from EEG (EEG features) |
Key inclusion & exclusion criteria
Age minimum | >= 45age old |
---|---|
Age maximum | <= 80age old |
Gender | Both |
Include criteria | <Healthy subjects> (1) Those who are between 45 and 80 years old at the time of obtaining consent. (2) Those who have received sufficient explanation and understanding of this research, and who have given their free and voluntary consent in writing. <patients with Alzheimer's disease> (1) Patients who are between 45 and 80 years of age at the time of consent. (2) Patients who have been diagnosed with probable Alzheimer's disease (AD) according to the NIA-AA diagnostic criteria1). (3) Those who have received sufficient explanation and understanding of this research and who have given their free and voluntary consent in writing. (4) A person who has been fully informed about this research and understands it, and who has given written consent of his/her own free will. Or, if the person lacks sufficient capacity to give consent, a person who has given written consent from a substitute. |
Exclude criteria | Healthy subjects Those with a history of or complications from neurological diseases Those who have performed MMSE or MoCAJ within 6 months Those with mental illness Those who are taking medication that may affect EEG measurement Those with severe complications (malignant tumor, myocardial infarction, heart failure, etc.) that may affect the amyloid beta PET CT test and EEG measurement Those whose physician judges that it is difficult to perform amyloid beta PET CT test due to some physical conditions (e.g., allergy to flutemetamol (18F)) Those who, for some reason (frontal trauma, frontal skin disease, skull defect, blindness, etc.), are considered to have difficulty in performing EEG measurement and tasks during EEG measurement Pregnant women, nursing mothers, and those who wish to become pregnant during the research period Those who are participating in other research. Other persons whom the researcher, etc. judges to be undesirable as subjects of this research. Patients with Alzheimer's disease Patients with a history of or complications from neurological diseases other than Alzheimer's disease Patients with mental illness Patients who are taking medication that may affect EEG measurement Patients with severe complications (malignant tumor, myocardial infarction, heart failure, etc.) that may affect amyloid beta PETCT test and EEG measurement Patients whose physician judges that it is difficult to perform amyloid beta PET CT test due to some physical conditions (e.g., allergy to flutemetamol (18F)) Patients who, for some reason (frontal trauma, frontal skin disease, skull defect, blindness, etc.), are considered to have difficulty in performing EEG measurement and tasks during EEG measurement Pregnant women, nursing mothers, and those who wish to become pregnant during the research period Those who are participating in other research. Other persons whom the researcher, etc. judges to be undesirable as subjects of this research. |
Related Information
Primary Sponsor | Takanami Kentaro |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Kentaro Takanami |
Address | 1-1 Seiryo-cho, Aoba-ku, Sendai, Miyagi Miyagi Japan 980-8574 |
Telephone | +81-22-717-7312 |
takanami@rad.med.tohoku.ac.jp | |
Affiliation | Tohoku University Hospital |
Scientific contact | |
Name | Kentaro Takanami |
Address | 1-1 Seiryo-cho, Aoba-ku, Sendai, Miyagi Miyagi Japan 980-8574 |
Telephone | +81-227177312 |
takanami@rad.med.tohoku.ac.jp | |
Affiliation | Tohoku University Hospital |